GEN Exclusives

More »

GEN News Highlights

More »
Jul 16, 2010

Bristol University Teams Up with Galapagos to Develop Neuropathic Pain Therapy

Bristol University Teams Up with Galapagos to Develop Neuropathic Pain Therapy

  • Galapagos could earn €3.3 million (about $4.2 million) in research fees over the next two years as part of a collaboration with Wellcome Trust researchers at the U.K.’s University of Bristol to develop treatments for diabetic neuropathic pain

    The partnership is focused on developing an analgesic based on the protein galanin, which Galapagos says has been shown to reduce neuropathic pain in a number of disease models including diabetes. The firm’s BioFocus service division will provide hit-to-lead and lead optimization services for the project, which is funded by a Wellcome Trust Seeding Drug Discovery Award.

    Project leader David Wynick, Ph.D., professor of molecular medicine at the University of Bristol, says studies suggest several compounds from BioFocus’ screening collection can amplify the therapeutic effect of galanin. “In this new collaboration with BioFocus, we aim to further optimize these molecules into potential clinical candidates for the treatment of chronic pain associated with diseases such as diabetes.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?